Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 9/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678843 | 0.93 | CCNC (0.42) | CCNCCDK8PRKDCPIK3CDPIK3CB | |
| SCHEMBL5217263 | 0.86 | HSD11B1 (0.32) | CCNCCDK8HSD11B1 | |
| Bromide SCHEMBL4465454 | 0.85 | HSD11B1 (0.32) | CCNCCDK8HSD11B1 | |
| SCHEMBL2678934 | 0.81 | CYP11B1 (0.41) | CCNCCDK8 | |
| SCHEMBL2677915 | 0.78 | CNR2 (0.41) | CCNCCDK8 | |
| SCHEMBL2679286 | 0.75 | AKT1 (0.36) | MAPT | |
| SCHEMBL5222614 | 0.75 | NPC1 (0.38) | HSD11B1 | |
| SCHEMBL2678761 | 0.74 | CYP11B2 (0.44) | CCNCCDK8 | |
| SCHEMBL2679129 | 0.74 | CYP11B1 (0.41) | HSD11B1TSHRLMNAMAPT | |
| SCHEMBL16547137 | 0.74 | ALOX5 (0.44) | PRKDCPIK3CDPIK3CBALOX5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759343-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| EP-2118104-B1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI SA (FR) | 2013-01-02 | — | — | EP | disclosed |
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI (FR) | 2012-08-09 | — | — | US | disclosed |
| US-8173669-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | CCNC 1208/4885CDK8 1436/4885PRKDC 254/4885 |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | CCNC 1208/4885CDK8 1436/4885PRKDC 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.